Skip to content

Context-dependent STAT3 signaling in liver fibrosis.

Jul 2026 · Hepatology · 0 citations
Medicine

TL;DR

A structured narrative synthesis of STAT3 regulation in liver fibrosis is provided to dissect the current status and challenges of targeted therapeutic strategies, and discuss how context-matched STAT3 modulation may inform future anti-fibrotic strategies.

Abstract

Liver fibrosis is a central pathological process driving the progression of chronic liver disease to cirrhosis and involves complex signaling networks across multiple cell types. Signal transducer and activator of transcription 3 (STAT3) serves as a signaling hub that integrates inflammatory, metabolic, and fibrogenic signals and exerts pleiotropic regulatory functions in liver fibrosis. STAT3 structure and subcellular localization provide the scaffold for signal encoding, whereas post-translational modifications (PTMs) alter STAT3 stability, dimerization, localization, transcriptional activity, and protein interactions. These regulatory states are further translated through direct transcriptional control, epigenetic mechanisms, non-coding RNA networks, signaling crosstalk, metabolic reprogramming, and oxidative stress into cell-specific phenotypes within the fibrotic microenvironment. Current evidence most consistently supports a pro-fibrotic role for STAT3 activation in HSC-centered fibrogenic programs, whereas several PTM-dependent, metabolic, and cell-protective mechanisms remain context-restricted or incompletely validated. Herein, we provide a structured narrative synthesis of STAT3 regulation in liver fibrosis, dissect the current status and challenges of targeted therapeutic strategies, and discuss how context-matched STAT3 modulation may inform future anti-fibrotic strategies.

View source

Similar papers

Review Open access Aug 2026

Decoding fibroblast activation: Transcriptional networks in hepatic stellate cells and across fibrotic organs (Review)

Current advances in understanding transcriptional regulatory networks governing fibroblast activation were summarized, with a primary focus on HSCs while highlighting shared mechanisms across multiple fibrotic organs.

Denita Charoenthanakitkul, Chaiyaboot Ariyachet · 0 citations
Review Open access Aug 2026

Epigenetic Regulation of Liver Fibrosis: Mechanisms and Therapeutic Implications

This review summarizes the principal epigenetic changes involved in HSC activation, initiation/progression of liver fibrosis, and discusses recent interventions designed to modulate these epigenetic changes.

M. J. Tavaf, M. E. Varkiani, Saeid Abroun et al. · 0 citations
Review Jul 2026

Epigenetic Regulation in Liver Fibrosis: Focus on the Chromatin Accessibility Landscape.

An in-depth study of the regulatory network of chromatin accessibility may provide new perspectives on the pathogenesis of liver fibrosis and lay a theoretical foundation for the development of novel precision-targeted drugs.

Xue Dong, Ming-Hui Li, Zheng-Lin Qiao et al. · 0 citations
Review Open access Aug 2026

Contribution of p38 MAPK in liver fibrosis: An overview of mechanisms, signaling pathways, and therapeutic targets (Review)

While p38 MAPK represents a promising therapeutic target for liver fibrosis, future research should focus on developing isoform-specific inhibitors, understanding context-dependent signaling outcomes, and designing combination therapies to enhance efficacy and minimize off-target effects.

Xueqin Yang, Hua-Rong Li, Hao-Sen Ye et al. · 0 citations
Review Aug 2026

Hypoxia-inducible factor-1 (HIF-1) in the molecular mechanisms of liver fibrosis: research progress on its role and therapeutic strategies.

The molecular regulatory network of HIF-1 in liver fibrosis is reviewed to provide theoretical support and identify future research directions for targeted therapy of liver fibrosis, thereby facilitating the clinical translation of relevant treatment approaches.

Cai-Yun Zhou, Li Wang · 0 citations
Review Jul 2026

Kinase regulation of miRNA networks in cardiometabolic disease: emerging pathways to precision therapy

A comprehensive framework of kinase-microRNA (miRNA) crosstalk as an emerging regulatory axis in cardiometabolic disease is presented, establishing kinase-miRNA crosstalk as a promising mechanistic framework and therapeutic target for precision intervention in heart failure, atherosclerosis, diabetic cardiomyopathy, an...

Firdos Ahmad, Asima Karim, M. Kannan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.